v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:      
Net income $ 54,448 $ 52,993 $ 50,612
Reconciliations of net income to net cash provided by operating activities:      
Depreciation and amortization 8,256 7,601 7,110
Non-cash operating lease expense 6,846 6,470 7,036
Investment amortization (accretion) and losses (gains) recognized 407 (221) 1,396
Losses recognized on disposal of property and equipment 72 65 256
Deferred income taxes 1,492 (854) 4,626
Share-based compensation 10,360 8,840 8,465
Changes in certain operating assets and liabilities:      
Trade accounts receivable (14,093) (63,126) (7,569)
Income taxes (303) 5,325 (8,597)
Prepaid expenses and other 46 (255) 1,344
Accounts payable 646 194 (1,671)
Accrued payroll and related benefits 22,597 55,170 5,698
Payroll taxes payable 12,778 (23,465) 7,030
Other accrued liabilities 8,785 (736) (4,177)
Premium payable (15,957) 7,886 54,168
Workers' compensation claims liabilities (23,558) (39,350) (51,246)
Operating lease liabilities (6,728) (6,668) (7,099)
Other assets and liabilities, net (139) 218 (160)
Net cash provided by operating activities 65,955 10,087 67,222
Cash flows from investing activities:      
Purchase of property, equipment and software (18,777) (14,160) (11,827)
Proceeds from sale of property and equipment   8 120
Purchase of investments (7,668) (7,902) (4,387)
Proceeds from sales and maturities of investments 15,983 23,319 10,352
Purchase of restricted investments (36,350) (29,971) (66,734)
Proceeds from sales and maturities of restricted investments 77,573 67,491 17,289
Net cash provided by (used in) investing activities 30,761 38,785 (55,187)
Cash flows from financing activities:      
Proceeds from credit-line borrowings 4,508 415 12,313
Payments on credit-line borrowings (4,508) (415) (12,313)
Repurchase of common stock (41,958) (29,133) (34,192)
Common stock repurchased on vesting of restricted stock units and performance awards (6,031) (4,837) (2,993)
Dividends paid (8,182) (8,086) (8,089)
Proceeds from exercise of stock options and purchase of ESPP 3,201 931 702
Net cash used in financing activities (52,970) (41,125) (44,572)
Net increase (decrease) in cash, cash equivalents and restricted cash 43,746 7,747 (32,537)
Cash, cash equivalents and restricted cash, beginning of period 82,588 74,841 107,378
Cash, cash equivalents and restricted cash, end of period $ 126,334 $ 82,588 $ 74,841

Source